Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eliem Therapeutics Inc (NQ: ELYM )

3.000 UNCHANGED
Streaming Delayed Price Updated: 10:59 AM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eliem Therapeutics Inc

< Previous 1 2 3 Next >
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
From Eliem Therapeutics, Inc.
Via GlobeNewswire
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
From Eliem Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce
 
Via Benzinga
Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study
 
Via Benzinga
Eliem Therapeutics: Q2 Earnings Insights
  Eliem Therapeutics (NASDAQ:ELYM) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023
 
Via Benzinga
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
From Eliem Therapeutics, Inc.
Via GlobeNewswire
Eliem Therapeutics Shares Fall On Lower Back Pain Trial Setback
 
Via Benzinga
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive... 
Via Benzinga
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
From Eliem Therapeutics, Inc.
Via GlobeNewswire
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
From Eliem Therapeutics, Inc.
Via GlobeNewswire
Eliem Therapeutics to Participate at Two Upcoming Investor Conferences
From Eliem Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022
Upgrades 
Via Benzinga
Eliem Therapeutics Provides Update on Pipeline Progress
From Eliem Therapeutics, Inc.
Via GlobeNewswire
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
Gainers 
Via Benzinga
SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To Know
  SVB Leerink has decided to maintain its Outperform rating of Eliem Therapeutics (NASDAQ:ELYM) and lower its price target from $9.00 to $4.00. Shares of Eliem Therapeutics are trading down 2.08% over... 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
Eliem Announces Updated Development Plans For Its Delayed Depression Candidate
In April, Eliem Therapeutics Inc (NASDAQ: ELYM) delayed ETX-155 into Phase 2a depression trials to determine the root cause of a lower-than-expected exposure observed in a Phase 1b study in... 
Via Benzinga
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday
Gainers 
Via Benzinga
SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To Know
SVB Leerink has decided to maintain its Outperform rating of Eliem Therapeutics (NASDAQ:ELYM) and lower its price target from $13.00 to $9.00. Shares of Eliem Therapeutics are trading down 4.04% over... 
Via Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Eliem Concludes Patient Enrolment In Mid-Stage Study Of Radicular Back Pain Drug
Eliem Therapeutics (NASDAQ: ELYM) has completed dosing of the last patient in its Phase 2a trial of ETX-810 in patients with chronic lumbosacral radicular pain (LSRP). 
Via Benzinga
5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.